Literature DB >> 16376652

Nasolacrimal duct obstruction classified by dacryoendoscopy and treated with inferior meatal dacryorhinotomy. Part I: Positional diagnosis of primary nasolacrimal duct obstruction with dacryoendoscope.

Tsugihisa Sasaki1, Yuuko Nagata, Kazuhisa Sugiyama.   

Abstract

PURPOSE: To investigate the site of primary nasolacrimal duct obstruction (PNLDO) using a dacryoendoscope and nasal endoscope.
DESIGN: Retrospective, observational case series.
METHODS: After local anesthesia, dacryoendoscopy and nasal endoscopy were performed in 149 cases (138 Japanese subjects) of PNLDO. Membranous nasolacrimal duct obstruction was termed as lower PNLDO, and occlusion at sac/duct junction termed as higher PNLDO.
RESULTS: The incidence of lower PNLDO was 26.8% (40 of 149 cases), and 109 cases (73.2%) were diagnosed with higher PNLDO.
CONCLUSIONS: The dacryoendoscope is extremely useful to observe directly and evaluate the site of obstruction with accuracy in PNLDO. The higher and lower PNLDO may have a different etiologies.

Mesh:

Year:  2005        PMID: 16376652     DOI: 10.1016/j.ajo.2005.07.038

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  17 in total

1.  Effect of rebamipide ophthalmic suspension on the success of lacrimal stent intubation.

Authors:  Masashi Mimura; Mari Ueki; Hidehiro Oku; Bunpei Sato; Tsunehiko Ikeda
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-10-20       Impact factor: 3.117

2.  Automatic screening of tear meniscus from lacrimal duct obstructions using anterior segment optical coherence tomography images by deep learning.

Authors:  Hitoshi Imamura; Hitoshi Tabuchi; Daisuke Nagasato; Hiroki Masumoto; Hiroaki Baba; Hiroki Furukawa; Sachiko Maruoka
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-02-12       Impact factor: 3.117

3.  Dacryoendoscopic observation and incidence of canalicular obstruction/stenosis associated with S-1, an oral anticancer drug.

Authors:  Tsugihisa Sasaki; Hiroaki Miyashita; Tamon Miyanaga; Katsushi Yamamoto; Kazuhisa Sugiyama
Journal:  Jpn J Ophthalmol       Date:  2012-03-13       Impact factor: 2.447

4.  Optimizing clinical outcomes for endoscopic lacrimal duct recanalization in patients with complete PANDO.

Authors:  Reynaldo M Javate
Journal:  Int Ophthalmol       Date:  2022-07-09       Impact factor: 2.031

5.  Liquid-based thin-prep cytology study of lacrimal drainage system in primary acquired nasolacrimal duct obstruction.

Authors:  Jeong-Kyeong Jang; Sung-Eun Choi; Helen Lew
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-04-26       Impact factor: 3.535

6.  Indications for and effects of Nunchaku-style silicone tube intubation for primary acquired lacrimal drainage obstruction.

Authors:  Masashi Mimura; Mari Ueki; Hidehiro Oku; Bunpei Sato; Tsunehiko Ikeda
Journal:  Jpn J Ophthalmol       Date:  2015-04-28       Impact factor: 2.447

7.  Transcanalicular endoscopic dacryoplasty in patients with primary acquired nasolacrimal duct obstruction.

Authors:  Sang Min Lee; Helen Lew
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-08-03       Impact factor: 3.117

8.  Evaluation of granulation tissue formation in lacrimal duct post silicone intubation and its successful management by injection of prednisolone acetate ointment into the lacrimal duct.

Authors:  Masashi Mimura; Mari Ueki; Hidehiro Oku; Bunpei Sato; Tsunehiko Ikeda
Journal:  Jpn J Ophthalmol       Date:  2016-04-26       Impact factor: 2.447

9.  Dacryoendoscopic surgery and tube insertion in patients with common canalicular obstruction and ductal stenosis as a frequent complication.

Authors:  Tsugihisa Sasaki; Tsutomu Sounou; Kazuhisa Sugiyama
Journal:  Jpn J Ophthalmol       Date:  2009-03-31       Impact factor: 2.447

10.  MR dacryocystography: comparison with dacryoendoscopy in positional diagnosis of nasolacrimal duct obstruction.

Authors:  Hiroki Higashi; Tsutomu Tamada; Kenichi Mizukawa; Katsuyoshi Ito
Journal:  Radiol Med       Date:  2016-04-05       Impact factor: 3.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.